Search Results - Rajwanshi, Richa
- Showing 1 - 3 results of 3
-
1
Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B C... by Samineni, Divya, Huang, Weize, Gibiansky, Leonid, Ding, Hao, Zhang, Rong, Li, Chunze, Sinha, Arijit, Rajwanshi, Richa, Humphrey, Kathryn, Bazeos, Alexandra, Salem, Ahmed Hamed, Miles, Dale
Published 2021Text -
2
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial by Samineni, Divya, Gibiansky, Leonid, Wang, Bei, Vadhavkar, Shweta, Rajwanshi, Richa, Tandon, Maneesh, Sinha, Arijit, Al-Sawaf, Othman, Fischer, Kirsten, Hallek, Michael, Salem, Ahmed Hamed, Li, Chunze, Miles, Dale
Published 2022Text -
3
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant by Redfield, Robert R., Jordan, Stanley C., Busque, Stephan, Vincenti, Flavio, Woodle, E. Steve, Desai, Niraj, Reed, Elaine F., Tremblay, Simon, Zachary, Andrea A., Vo, Ashley A., Formica, Richard, Schindler, Thomas, Tran, Ha, Looney, Caroline, Jamois, Candice, Green, Cherie, Morimoto, Alyssa, Rajwanshi, Richa, Schroeder, Aaron, Cascino, Matthew D., Brunetta, Paul, Borie, Dominic
Published 2019Text